secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001070081-26-000006
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics reports positive PIVOT-HD extension data: 52% slowing of HD progression at 10 mg votoplam
--------------------------------------------------------------------------------

- Stage 2 HD participants showed 52% (10 mg) and 28% (5 mg) slowing on cUHDRS vs natural history at 24 months.
- Mean NfL levels remained below baseline at 24 months for both doses, contrasting with natural history increases.
- Safety data at Month 24 consistent with prior favorable safety profile; no treatment-related NfL increases.
- Novartis has initiated global Phase 3 INVEST-HD study of votoplam (10 mg vs placebo, n≈770, primary endpoint cUHDRS at 36 months).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008126000006/0001070081-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008126000006/tmb-20260428x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer